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NHIBITION OF DISEASES ASSOCATED WITH AMYLOD FORMATION BACKGROUND OF THE INVENTION
Amyloid plaque formation is found in a number of diseases including Alzheimer's Disease (AD), scrapie, bovine spongiform encephalopathy, Gerstmann Straussler Syndrome and related transmissible spongi form encephalopathies (TSEs). These amyloid plaques comprise protein molecules bound together in a fibri nous matrix. Other disorders, such as Creutzfeldt Jakob's disease, are characterized by the accumulation of amyloidogenic protein without deposition of amyloid plaques. Together these groups of conditions are re ferred to herein as "Amyloidogenic Diseases."
Amyloidogenic diseases include a heterogeneous group of hereditary and nonhereditary disorders related by their production of amyloid-forming proteins. These disorders are often accompanied by extracellular depo sition of amyloid plaques in one or more tissues. An amyloid plaque is identified by its amorphous, eosino philic, homogeneous appearance. A unique green bire fringence after Congo Red staining, fibriflar ultrastruc ture, and cross beta X-ray diffraction pattern are also features of amyloid plaques.
The presence of amyloid plaques in various tissue samples can indicate a vast array of diseases. Alzhei mer's disease is now identified by the presence of cere bral amyloid plaques derived from beta protein. Adult Type II diabetes can be identified by the presence of the amyloidogenic protein IAPP in amyloid plaques from pancreatic islets.
Some methods of affecting amyloidogenic protein accumulation have been developed. However, no gen eral therapy directed towards many Amyloidogenic Diseases has yet been developed.
In one study of factors affecting amyloid protein accumulation, the drugs melphalan and prednisone were compared with the known protein inhibitor col chicine. Patients treated with colchicine had a median survival of 18 months compared to a control group who survived, on average, only six months. Patients treated with melphalan and prednisone survived 25 months. This study showed no significant difference in survival between subjects in any group, although the trend fa vored melphalan and prednisone.
Other modes of therapy have included the use of dimethyl sulfoxide and treatment of secondary amyloid with affiylating agents. An experimental fish oil diet in mice has also been studied.
In selected patients with systemic amyloidosis and azotemia, renal transplantation has exhibited effective ness. Normal renal function may be present for a period of time after transplantation, although amyloid plaques may subsequently develop. Three year graft survival in patients receiving primary cadaveric kidney grafts has been reported, but overall survival of patients with amyloidosis has been worse than patients undergoing transplantation for glomerulonephritis. Notwithstand ing the partial success of transplantation, a non-surgical intervention would be more desireable.
In scrapie, Creutzfeldt-Jakob's disease, bovine spon giform encephalopathy, and related transmissible spon giform encephalopathies, an abnormal protease-resist antisoform of the endogenous prion protein (PrP) accu mulates in the CNS and other tissues. Unlike the nor mal, protease-sensitive PrP (PrP-sen), the protease resistant PrP (PrP-res) is insoluble in many detergents and can aggregate into amyloid-like plaques with high 0 -sheet content. Although the etiology of these TSEs is not clear, evidence exists that PrP plays an important role in the pathogenesis of these diseases.
Some investigators have proposed that PrP-res is a component of the infectious agent or is itself the agent, but this issue remains highly controversial. Studies of the mechanism of PrP-res formation, the relationships of PrP-res to pathogenesis and infectivity, and potential therapies for the TSEs would be aided greatly by the availability of a compound that selectively inhibits the accumulation of Prp-res.
The structure of Congo Red dye is shown below:
Congo Red is known to bind amyloid plaques, including those comprised of PrP-res protein. See Prusiner et al., Cell, . Congo Red has also been re ported to inhibit experimental casein-induced amyloid deposition in mice (Kagan et al., Problemy Tuber kuleza, 9:72-74 (1974 In a preferred form of the invention, the method is useful for treating, preventing and/or inhibiting condi tions associating with plaques occurring in a tissue of the central nervous system of said mammal. In another form, the method useful against a disease of the internal organs related to amyloid plaque formation, including plaques in the heart, liver, spleen, kidney, pancreas, brain, lungs and muscles. Thus, in this form, the method includes treatment of Adult type II diabetes where the plaques occur in the pancreas. In still other forms of this aspect of the invention the condition is associated with deposition of a variant form of cystatin-C, such as HCHWA-I, or a form of amyloid precursor protein (APP), such as AD or HCHWA-D. In yet another aspect of the present invention, there is provided a method of inhibiting the transformation of PrP-sen to PrP-res in a tissue culture sample containing PrP-sen. In this aspect, Congo Red or a salt or deriva tive thereof in an amount effective to interfere with PrP-res formation is applied to the sample. In a pre ferred form of this aspect, the sample can include COST cells.
The present invention includes still another aspect in which a method of treating a mammal, such as a human, having a condition associated with overproduction of PrP-res is provided. In this aspect, such a mammal is identified and treated with Congo Red in a manner, such as that described above in the foregoing aspects of the invention.
In still a further aspect of the present invention, there is provided a method of treating a mammal having a chronic infection associated with Acquired Amyloid protein. These infections include tuberculosis, osteomy elitis, rheumatoid arthritis, granulomatous ileitis, and Mediterranean fever. The method includes identifying such a mammal and administering Congo Red, in a manner such as that described above for other aspects of the invention.
In yet one more aspect of the present invention, a method of treating a mammal having multiple myeloma associated with Idiopathic Amyloid protein is provided. 
DETAILED DESCRIPTION
The Applicants' have discovered that Congo Red not only binds amyloid plaques, but can also inhibit the accumulation of amyloidogenic protein. In this regard, Applicants have further discovered that administration of Congo Red to a mammal in vivo can provide effec tive treatment, prevention and/or inhibition of many, if not all Amyloidogenic Diseases. In particular, the in vention can be used for both Amyloidogenic Diseases associated with deposition of amyloid plaques and Amyloidogenic Diseases, such as Creutzfeldt-Jakob Disease, in which formation of amyloidogenic protein occurs without deposition of amyloid plaques. The ultimate treatment of the present invention is aimed at decreasing amyloidogenic protein accumulation and deposition by inhibiting its formation or decreasing its metabolic stability.
Amyloid plaques comprise amyloidogenic protein molecules bound in a fibriflous matrix and deposited on the cell surface. The present invention describes a method of inhibiting the accumulation of these plaque forming proteins in vitro and in vivo by Congo Red.
It is now possible to clinically classify the various amyloid proteins based on the nature of their biochemis try. Applicants believe that inhibition of the accumula tion of these types of amyloidogenic proteins by Congo Red would inhibit amyloid fibril formation possibly leading to cessation or stabilization of the disease state. Table I lists a variety of Amyloidogenic Diseases along with their associated amyloidogenic proteins. 5,276,059 5 Applicants believe that Congo Red has the ability to reduce the amount of amyloidogenic protein produc tion associated with many Amyloidogenic Diseases, inlcuding those listed in Table 1 . Thus, the administra tion of Congo Red to a mammal having one of these conditions is believed to be beneficial in the inhibition, prevention and treatment of these diseases. In Vivo Experiment. Using Syrian Hamsters Female Syrian hamsters (available from Charles River Labs) normally develop amyloidosis of the liver, spleen and kidney one year after birth, resulting in a much shorter life expectancy for females than for males (Coe & Ross, J. Clinical Investigation 76:66-74 (1985) ). The amyloidosis can be accelerated markedly by the administration of diethylstilbestrol (DES) so that it occurs within 2-3 months of initiating treatment.
To determine the effects of Congo Red on amyloid osis in this model, four groups of hamsters are con pared. The first group (10 hamsters) are given DES pellets at 3 months of age followed by a continuous 
AL Protein
Another type of amyloid plaque comprises the AL protein, normally detected in patients with multiple myeloma. AL protein consists of a variable region por tion of either the kappa or lambda immunoglobulin light chains. In some cases the entire kappa or lambda protein molecule is detected. While kappa chain amyloids are prevalent in multiple myeloma and monoclonal gam mopathies, the incidence of lambda chain amyloids predominates by a 2:1 ration. The AL protein amino acid sequence is identical from afl the organs of any one patient. Virtually all kappa and lambda chain proteins known to date are amyloidogenic although some seem to be more susceptible to plaque formation than others.
Amyloid Beta Protein It has been known for years that brain tissue from Alzheimer's disease (AD) patients contained amyloid plaques which were stainable with Congo Red. Amy loid fibrils from the cerebral blood vessels of AD and from Down's syndrome patients were isolated and found to be caused by the amyloid beta protein (AIBP). This protein has now been accepted as a probable factor 5,276,059 7 in the pathogenesis of AD. Alpha-1 antichymotrypsin (a serine proteinase inhibitor) was also shown to be inti mately associated with beta protein in AD. An enor mous number of studies have been done confirming that APB derives from an amyloid precursor protein (APP or ABPP).
In the Dutch type cerebral amyloid with hemorrhage syndrome, the amyloid plaque also comprises a beta protein but with a variant amino acid (Gln22 
Amyloid Formation
Extensive studies have been carried out to assess common factors or substances related to all the amy loid-forming proteins, so far without success. However, the most prominent mechanism proposed for amyloid formation involves the P component of amyloid (AP) and its serum counterpart (SAP). Electron microscopy reveals that AP is a 230 kD protein composed of a pair of pentagonally shaped subunits. AP may serve as a scaffold for amyloid fibril formation.
When isolated, AP is distinct from an amyloid plaque, does not bind Congo Red, and is without any fibrillar ultrastructure or cross beta pattern. However, AP has been found in virtually an known forms of amyloid. Glycosaminoglycans (GAGS) have also been promi nently associated with amyloid. Multiple studies have attempted to relate specific GAGs to amyloid deposits. Since most amyloids are associated with highly sulfated GAGS, it has been postulated that these very nega tively charged molecules affect the protein product or precursor processing.
Traditional studies have regarded amyloid formation as a two-phase process. In the first phase, the produc tion of amyloidogenic precursor proteins is initiated. In the second phase, amyloid fibril deposition or process ing occurs. Amyloid enhancing factor (AEF) is known to, for example, shorten either the lag between phases or induction time. This elusive substance has been found in both animal and human amyloid plaques, but is not yet precisely characterized.
Applicants believe that Congo Red can inhibit amyloidogenic protein production at the first phase of the process. Thus, Applicants believe that Congo Red provides a general method of treatment, prevention and inhibition that is common to all Amyloidogenic Dis
CSCS

Identification of Amyloidosis
Amyloidosis is normally suspected in individuals with unexplained renal disease, especially those with nephrotic syndrome. Also suspect are individuals with hepatosplenomegaly in association with certain chronic inflammatory disorders such as rheumatic disease. Patients with AL amyloidosis frequently have Bence Jones proteins alone or in association with a serum monoclonal protein. In patients suspected of having AL amyloidosis, an examination of the bone marrow can document the underlying plasma cell dyscrasia or possi ble myeloma. This type of examination can also be used to search for amyloid infiltrates, which can often be found in bone marrow.
Reactive (AA) (secondary) amyloid is classically associated with chronic inflammatory and infectious diseases. In recent years, it has become apparent that amyloid may complicate Crohn's disease with an inci dence of at least 1% and that it is a serious complication of chronic drug abuse. Patients with cystic fibrosis have also been found to have amyloidogenic plaques. Specific clinical manifestations of amyloidosis vary enormously, depending greatly on the involved organ and the extent of the deposits. The following comments refer largely to generalized (systemic) amyloid, i.e., reactive (secondary), idiopathic (primary) or heterofamilial, respectively.
Renal involvement is common in almost all forms of systemic amyloid, ranging from mild urinary red blood cell loss or mild proteinuria to extensive nephrosis. A renal lesion is usually irreversible possibly leading to progressive azotemia.
Hepatic enlargement from amyloid deposition is common, while signs of portal hypertension from he patic amyloid plaques are uncommon. Hepatic cholesta sis with severe liver involvement can also occur due to amyloidosis, although liver function abnormalities, es pecially elevated serum alkaline phosphatase, are usu ally minimal, occurring late in the disease. Liver scans are known to produce variable and nonspecific results.
Gastrointestinal symptoms in amyloidosis are very common and result from direct involvement of the gastrointestinal tract from infiltration of the autonomic nervous system with amyloid. The symptoms include those of obstruction, ulceration, hemorrhage, malab sorption, protein loss and diarrhea. Cardiac manifestations of amyloidosis consist primar ily of congestive heart failure and cardiomegaly. Intrac table heart failure may be the first manifestation and is the major cause of death in patients with generalized amyloidosis. Although cardiac manifestations normally indicate predominantly diffuse myocardial amyloid plaques, the endocardium, valves, and pericardium may be involved.
Clinically significant amyloid heart disease is con mon in the AL form and rare in AA form of the amyloid plaque. In an echocardiographic study of 28 patients with FAP, it was shown that heart disease develops slowly but progressively and that left ventricular dia stolic abnormalities precede the development of clini cally overt heart disease. Isolated cardiac amyloidosis 5,276,059 9 itself has been reported as a cause of sudden death.
Finally, senile cardiac amyloid has been shown to be a cause of congestive heart failure.
Amyloid is identifiable in the skin in over one-half of patients with primary or secondary disease, whether or not clinically apparent lesions are present. The lesions vary widely from waxy, often translucent, papules or plaques to nodules or tumefactions. Purpuric areas may be present. The lesions are seldom pruritic. Involve ment of the skin or mucosa may not be apparent even on close inspection but may be discovered at biopsy. Pa tients with hereditary amyloid neuropathy have posi tive skin biopsies for amyloid in most cases.
Amyloidosis is infrequently seen in the synovium of patients with AA (secondary) disease, but it has been found in AL (primary) and in disease associated with chronic hemodialysis (beta-2-microglobulin). In rare instances of AL it can mimic rheumatoid arthritis and has been associated with a fullness in the shoulder called the "shoulder pad syndrome'. It has surprisingly a fre quent association with osteoarthritis. Amyloidosis can also accumulate in the muscles causing a frank myop athy.
The B2M amyloid of chronic hemodialysis was first found in the lesions of carpal tunnel syndrome, but is now known to cause an extraordinary variety of bone and joint lesions ranging from carpal tunnel syndrome to destructive arthropathy and cystic bone lesions. Kid ney transplants have been shown to halt the progression and cause symptomatic relief, but have not as yet been shown to reverse the lesions.
Neurologic manifestations that are especially promi nent in the classic hereditary neuropathies include pe ripheral neuropathies with early sensorimotor dissocia tion, and autonomic nervous system involvement with constipation, diarrhea, impotence, and postural hyper tension. Except for the Finnish variety of hereditary neuropathy, cranial nerves other than those involving pupiuary reflexes are generally spared.
It has been well known for many years that reactive (secondary, AA) amyloidosis is a major complication of rheumatoid arthritis. The early literature reported its incidence in a variety of ways, including renal biopsies, rectal biopsies, Congo Red tests, gingival biopsies, and with a variety of tissue stains, such that its true inci dence was not clear.
The earlier literature was also affected by the method in which amyloid was diagnosed in the tissue. Crystal violet metachromasia and other histochemical and fluo rescent stains as well as Congo Red were utilized. The current standard for amyloid identification is the dem onstration of green birefringence on polarization mi croscopy after Congo Red staining and has been gener ally accepted in the literature since 1980. Although Congo Red has been used as a stain to identify many of the above disease states, Applicants have discovered that Congo Red can be used in vivo to inhibit amyloido genic protein accumulation. Treatment of Amyloidosis Condition without Plaque Formation As stated above, a number of Amyloidogenic Dis eases in mammals occur without actual completion of the plaque forming phase. In this diseases, the amyloido genic proteins themselves are involved in the diseases producing process. Cruezfeldt-Jakob Disease is one example of such a disease. The Applicants believe that a mammal suffering from amyloid protein production can be effectively treated by administration of a pharmaceutically effective com position of Congo Red. For instance, Congo Red (or its pharmaceutically acceptable salt or derivative) can be given to a mammal in need of such a treatment by oral or parenteral administration. Preferred administration methods include intravenous injection,transdermal ad ministration, intraperitoneal injection, subcutaneous injection, intramuscular injection, intrasternal injection, intrathecal injection or direct infusion techniques.
Use of appropriate Congo Red derivative compounds that retain the ability of Congo Red to interfere with generation and/or deposition of amyloidogenic protein are included within the scope of the present invention.
Preferred dosages in the treatment of Amyloidogenic Diseases in mammals are generally in the range of 1 ug/kg to 100 mg/kg. More preferably, the dosage is between 0.01 mg/kg and 10 mg/kg.
The A patient suffering with a transmissible spongioform encephalopathy (TSE) is intravenously injected with a pharmaceutically effective concentration of Congo Red. Prior to treatment, a tissue biopsy finds that the patient has a large number of amyloid plaques compris ing PrP-res. The Congo Red solution is injected into the patient in a phosphotidylcholine carrier. The number of amyloid plaques in a secondary tissue biopsy finds a reduction in the number of PrP-res amyloid plaques after Congo Red treatment. Reducing number of amy loid plaques results in a further medical improvement of the patient. This is one method of successfully treating a patient diagnosed with TSE using Congo Red. Another example of using Congo Red in the preven tion of an Amyloidogenic Disease associated with depo sition of PrP-res is provided below. In this example, the Amyloidogenic Disease is scrapie in mice.
Weanling random bred RML Swiss mice were inocu lated intraperitoneally with 50 l 1% brain homogenate from mice clinically ill with scrapie (Chandler strain) containing 10-10 LD50 scrapie agent. One group of eight mice was given twice weekly intraperitoneal in jections of 0.5 mg Congo Red (in sterile water) starting within 6 hours of the scrapie inoculation. A control group of eight mice was given intraperitoneal injections of water alone.
After five weeks, the spleens were harvested from all the animals. The pulp cells from individual spleens were sonicated, treated for 1 h with 33 g/ml DNAase A (37' C.), combined with an equal volume of 20% sarko syl, and centrifuged at 10,000 rpm in a Beckman TL100.4 rotor for 30 min. The supernatants were then centrifuged at 70,000 rpm for 2 hr. The pellets were resuspended in 10 mM Tris-HCL, pH 7.5, sonicated, treated with 10 jig/ml proteinase K for 30 min (37' C.) and then repelleted at 70,000 rpm. The pellets were then analyzed for PrP-res by immunoblot using anti-PrP antiserum using standard procedures. The average in munoblot signal intensity of PrP-res from spleens of Congo Red injected animals was 87% less than the average control value. This result suggests that Congo Identically seeded, nearly confluent 25-cm2 flasks of scrapie-infected mouse neuroblastoma cells (Race, et al. 1988) were rinsed twice with phosphate-buffered bal anced salt solution and preincubated in 2 mi of methio nine-free and cysteine-free minimal essential medium with 1% dialyzed fetal bovine serum at 37' C. After 30 min. an aqueous concentrate of Congo Red (Sigma) was added to the medium to give the designated final con centrations. Immediately thereafter, 380 lici of TranS label (ICN) was added to each flask for a 2-h pulse labeling. Following the radiolabled nucleotides was 10 ml of chase medium (complete minimal essential me dium with 10% fetal bovine serum) containing the des ignated Congo Red concentration, and incubation con tinued for 16 h to allow the labeling of PrP-res.
Cell lysates were prepared by standard protocols and, following the removal of aliquots for the total labeled protein analysis, radiolabeled PrP-res concentrations were measured using a previously described procedure (Caughey and Raymond, 1991) . In brief, the lysates were treated with proteinase K and ultracentrifuged to isolate Prp-res. The PrP-res was then solubilized, in munoprecipitated with a rabbit antiserum to PrP pep tide 89-103 (Caughey et al. J. Virol 65:6597-6603 (1991) , and analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and fluor ography. A 20% acrylamide Pharmacia LYB PHAST SYSTEMO gel was used for the SDS-PAGE.
Release of Labeled Prp-sen from Intact Cells
Nearly confluent flasks of cells were preincubated with fresh minimal essential medium containing 10% fetal bovine serum for 20 h. The ceils were then rinsed, preincubated in methionine-and cysteine-free medium, labeled with 100 uCi of TranS-label for 90 min, and chased for 30 min according to the general procedure described above. After rinsing with phosphate-buffered balanced salts solution, the cells were incubated for 30 min at 37' C. with phosphatidyl-inositol-specific phos pholipase C (PIPLC) from Bacillus thuringiensis (Low, et al. (1988) C. J. Immunol Methods 113: 101-111) at an activity of 1.6 limol/min. The PIPLC media was centri fuged at 1,000 g for 2 min, and the supernatants adjusted to a final concentration of 0.5% sodium deoxycholate, 0.1% SDS, 1% Nonidet P-40, 0.15 M. NaCl, 1 mM EDTA,01.% gelatin, 50 mM Tris-HCl (pH 8.0).5ul of antiserum R34 was added to precipitate the PrP-res. The remainder of the immunoprecipitation and analysis by SDS-PAGE-fluorography (12.5% acrylamide gel) was performed as described previously (Caughey, et al., 1991a) .
Immunoblotting PrP-res separated on a 20% acrylamide gel was electrophoreticauy transferred onto a polyvinyl difluo ride membrane (Miljipore) using the Pharmacia LKB PHASTSYSTF-MO The Membrane was blocked with 5% nonfat dried milk in 10 mM Tris-HCI (pH 8.0), 150 mMNaCl, and 0.05% Tween-20 (TBST). The filter was incubated for 2 h at ambient temperature with anti-PrP serum diluted 1:1000 in TBST. After washing in TBST, the filter was strained with horseradish peroxidase-con jugated goat anti-rabbit immunoglobulin and the ECL luminescence detection kit (Amerisham). Estimates of the relative amounts of PrP-res detected in the immuno blot lanes were obtained by comparing the film expo sure times giving densitometrically equivalent band intensities.
In vitro Results
The effect of Congo Red on the accumulation of newly synthesized PrP-sen in scrapie-infected neuro blastoma cultures was tested by metabolically labeling PrP-res in the presence of Congo Red.
Concentrations of Congo Red greater than 1.4 uM nearly eliminated detectable labeling of PriP-res ( Because the two generally recognized hallmarks of PrP-res are its protease resistance and its aggregated state, a protocol was used employing both proteinase K treatment and ultracentrifugation to discriminate PrP res from normal PrP. In addition, to test for the possibil ity that Congo Red decreased the proteinase K resis tance of Prp-res without affecting its aggregation state, or vice versa, the experiment was repeated using only proteinase K treatment (followed by methanol precipi tation) or ultracentrifugation of the cell lysates before the solubilization and immunoprecipitation of PrP-res. In each case, Congo Red-dependent reductions in PrP res labeling were observed, indicating that Congo Red inhibited the labeling of PrP-res as defined by either aggregation or proteinase K resistance. The inhibitory effect of Congo Red appeared to be selective for PrP res since the highest concentrations of Congo Red tested (42 uM) did not change the overall profile of labeled proteins in the cell lysates before proteinase K treatment (FIG. 1B) . Furthermore, there were no ef. fects of these Congo Red treatments on cellular mor phology.
Since phospholipase-sensitive, cell surface (PrP-sen) is the precursor of PrP-res (Caughey and Raymond, J. BioL Chem. 266:18217-18223 (1991) ), it is possible that the newly discovered Congo Red inhibition of PrP-res labeling could be indirectly due to PrP-sen biosynthesis, turnover, or transport to the cell surface. However, 1.4 uM Congo Red had no influence on the 35Smethio nine labeling and rate of degradation of PrP-sen (FIG.  2) or the release of labeled PrP-sen from the cell surface by PIPLC (FIG. 3) . These observations provided evidence that, rather than affecting normal PrP metabolism, Congo Red specifically prevented PrP-res formation or greatly reduced its metabolic t.
The longer-term effect of Congo Red on the total PrP-res content of scrapie-infected neuroblastoma cul tures was also tested. Inclusion of submicromolar con centrations of Congo Red in the growth medium of 5-day cultures caused profound reductions in the total PrP-res content detected by immunoblot using three distinct antisera raised against peptides corresponding to PrPresidues 89-102 (FIG. 4) , 142-155, and 218-232. For instance, in FIG. 4 , the intensity of PrP-res bands from the ceils treated with 0.14 LM Congo Red wa s (10% of control intensity. To control for the possibility that residual Congo Red in the lysates artifactually interfered with the immuno chemical detection of PrP-res, 14 M of Congo Red was added to a control cell lysate before proteinase K digestion step. There was no reduction in the PrP-res signal detected by the extraction and immunoblot pro cedure using anti-PrP peptide 89-102. The treatment of the cells with Congo Red (up to 14 M) had no signifi cant effect on the growth of the cultures because the total protein content in the lysates of the Congo Red treated cells was within 85% of the control values in all cases. Again, no changes in cell morphology were ob served. Thus, without overt signs of cytotoxicity, Congo Red greatly reduced the amount of PrP-res produced by the infected neuroblastoma cultures.
Mechanism of Action
The mechanism for the inhibition of the accumulation of PrP-res and other amyloidogenic proteins by Congo Red is not known. However, because Congo Red binds to amyloid fibrils of PrP-res it is likely that this direct interaction interferes with a critical event in the forma tion of amyloidogenic protein or destabilize the struc ture once it is formed. Destabilization of amyloidogenic protein could make it susceptible to degradation by the endogenous proteases to which it is exposed. Woody et al., Biochim. Biopys, Acta 655:82-88 (1981) , have suggested that Congo Red can stack extensively and act as a polyanion. This theory is bolstered by Ap plicants' discovery that Congo Red can serve to pro long the lifespan of scrapie-infected mammals, since prophylactic administration of certain polyanions has 15 also been shown to prolong the lifespan of animals inoc ulated with scrapie (Kimberlin and Walker, Antimicrob, Agents Chemother 30: 409-413 (1986) ).
As stated earlier, use of appropriate derivative com pounds that retain the ability of Congo Red to interfere with generation and/or deposition of amyloidogenic protein are included within the scope of the present invention. Thus, appropriate Congo Red derivate com pounds for use within the scope of the present invention will include those that do not interfere with the forma tion of polyanion-like activity in the derivative.
Conclusion
The foregoing detailed description has exemplified Applicants' discoveries with reference to certain partic ular amyloidogenic proteins and Amyloidogenic Dis eases. However, Applicants have discovered a method of treatment, prevention and/or inhibition that is com mon to many Amyloidogenic Diseases. Other discover ies also form a part of the present invention. Thus, the scope of the present invention can be interpreted with reference to the appended claims. 6. The method of claim 5, wherein the administering step comprises a technique selected from the group consisting of transdermal administration, subcutaneous injection, intravenous injection, intraperitoneal injec tion, intramuscular injection, intrasternal injection, in trathecal injection and infusion techniques. 10. The method of claim 9, wherein said condition is selected from the group consisting of scrapie and trans missible spongioform encephalopathies (TSE's). 11. The method of claim 9, wherein the administering step comprises oral administration of Congo Red into said mammal.
12. The method of claim 9, wherein the administering step comprises parenteral administration of Congo Red into said mammal.
13. The method of claim 12, wherein the administer ing step comprises a technique selected from the group consisting of transdermal administration, subcutaneous injection, intraperitoneal injection, intravenous injec tion, intramuscular injection, intrasternal injection, in trathecal injection and infusion techniques.
14. The method of claim 9, wherein the administra tion step comprises administering Congo Red along with a lipophilic solvent or carrier.
15. administering to said mammal a pharmaceutically effective amount of Congo Red or a salt or deriva tive thereof to interfere with amyloidogenic pro tein formation or to destabilize amyloidogenic pro tein structures already formed in said mammal.
